期刊文献+

蛋白激酶抑制剂PKC412对膀胱癌T24细胞生长增殖的影响

Inhibitory effects of PKC412 on the growth and prolification of human bladder cancer cell T24 in vitro
下载PDF
导出
摘要 目的:观察蛋白激酶C(PKC)抑制剂N苯甲酰星孢菌素(PKC412)对膀胱癌T24细胞株生长、增殖、侵袭功能和细胞周期的影响。方法:用不同浓度PKC412(0.01,0.1,1.0,10μmol/L)作用于对数生长期T24细胞24,48,72 h。采用软琼脂克隆形成试验测定T24细胞克隆形成抑制率,MTT法检测细胞生长抑制率,Transwell小室法检测细胞的侵袭能力,流式细胞术分析细胞周期的变化。结果:当PKC412浓度从0.01μmol/L增加到10μmol/L时,T24细胞克隆形成抑制率从-0.62%增加到80.46%,细胞生长抑制率从1.17%增加到73.62%,细胞侵袭抑制率从1.8%增加到73.72%(P<0.05),均呈时间和剂量依赖性。PKC412作用48 h后,随着浓度的增加,G2/M期细胞比例从12.26%增加到58.41%,呈G2/M期细胞阻滞。结论:PKC412对体外培养的T24细胞克隆形成、生长和侵袭具有抑制作用,其机制与G2/M期细胞阻滞有关。 Objective: To investigate the growth,proliferation,invasive function and the influence of the cell cycle of PKC412 on T24 bladder cancer in vitro.Methods: With different concentrations of PKC412(0.01,0.1,1,10 mol/L)acted on the T24 cell after 24,48,72 h;using soft agar clonogenic assay to determine the cell colony formation inhibition rate of T24,MTT method was used to detect the cell growth inhibition rate.The invasion ability of T24 was assayed by Transwell cell,the cell cycle changes were analysed by flow cytometric.Results: The inhibition rate of T24 cell clone forming from-0.62% increased to 80.46%,when PKC412 concentration increased from 0.01 μmol/L to 10 μmol/L;cell growth inhibition rate increased from 1.17% to 73.62%,the cells invasive inhibition rate increased from 1.8% to 73.72%.All inhibitions were in a time-and-dose dependent manners.After PKC412 acting 48 hours,with the increasing of concentration,G2/M period cells from 12.26% increased to 58.41%,showed the G2/M period cell block.Conclusion: PKC412 decreased cell growth,invasion and inhibited cloning formation of human bladder cancer cell T24 in vitro.
作者 张建国 苏昀
出处 《江苏大学学报(医学版)》 CAS 2011年第6期476-480,共5页 Journal of Jiangsu University:Medicine Edition
基金 江苏省卫生厅面上科研基金资助项目(H200813)
关键词 膀胱癌 N苯甲酰星孢菌素 克隆 侵袭 细胞周期 bladder cancer N-benzoyl-staurosporine clone invasion cell cycle
  • 相关文献

参考文献8

  • 1Heidel F,Solem FK,Brieitenbuecher F,et al.Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain[J].Blood,2006,107(1):293-300.
  • 2Monnerat C,Henriksson R,Le Chevalier T,et al.Phase Ⅰstudy of PKC412(N-benzoyl-staurosporine),a novel oral protein kinase C inhibitor,combined with gemcitabine and cisplantin in patients with non-small-cell lung cancer[J].Ann Oncol,2004,15(2):316-323.
  • 3Fischer T,Stone RM,Deangelo DJ,et al.Phase IIB trial of oral Midostaurin (PKC412),the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor,in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3[J].J Clin Oncol,2010,28(28):4339-4345.
  • 4El Fitori J,Su Y,Büchler P,et al.PKC412 small-molecule tyrosine kinase inhibitor:single-compound therapy for pancreatic cancer[J].Cancer,2007,110(7):1457-1468.
  • 5Kim M,Park IY,Lim J,et al.Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer[J].Ann Clin Lab Sci,2006,36(4):455-600.
  • 6Huang YC,Shieh HR,Chen YJ.Midostaurin (PKC412) modulates differentiation and maturation of human myeloid dendritic cells[J].Toxicol In Vitro,2010,24(6):1705-1710.
  • 7Aaltonen V,Koivunen J,Laato M,et al.PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells[J].Cancer Lett,2007,253(1):97-107.
  • 8Hemstrm TH,Joseph B,Schulte G,et al.PKC412 sensitizes U1810 non-small-cell lung cancer cells to DNA damage[J].Exp Cell Res,2005,305(1):200-213.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部